2023-11-01 2024-10-31 false Capium Accounts Production 1.1 14392434 2023-11-01 2024-10-31 14392434 bus:AbridgedAccounts 2023-11-01 2024-10-31 14392434 bus:FRS102 2023-11-01 2024-10-31 14392434 bus:AuditExemptWithAccountantsReport 2023-11-01 2024-10-31 14392434 bus:SmallCompaniesRegimeForAccounts 2023-11-01 2024-10-31 14392434 bus:PrivateLimitedCompanyLtd 2023-11-01 2024-10-31 14392434 2023-11-01 2024-10-31 14392434 2024-10-31 14392434 bus:RegisteredOffice 2023-11-01 2024-10-31 14392434 core:WithinOneYear 2024-10-31 14392434 core:AfterOneYear 2024-10-31 14392434 1 2023-11-01 2024-10-31 14392434 bus:Director1 2023-11-01 2024-10-31 14392434 bus:Director1 2024-10-31 14392434 bus:Director1 2022-10-13 2023-10-31 14392434 2022-10-13 14392434 bus:LeadAgentIfApplicable 2023-11-01 2024-10-31 14392434 2022-10-13 2023-10-31 14392434 2023-10-31 14392434 core:WithinOneYear 2023-10-31 14392434 core:AfterOneYear 2023-10-31 14392434 bus:EntityAccountantsOrAuditors 2022-10-13 2023-10-31 14392434 bus:OrdinaryShareClass1 2023-11-01 2024-10-31 14392434 bus:OrdinaryShareClass1 2024-10-31 14392434 bus:OrdinaryShareClass1 2022-10-13 2023-10-31 14392434 bus:OrdinaryShareClass1 2023-10-31 14392434 core:ComputerEquipment 2023-11-01 2024-10-31 14392434 core:ComputerEquipment 2024-10-31 14392434 core:ComputerEquipment 2023-10-31 14392434 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-10-31 14392434 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-10-31 14392434 core:CostValuation core:Non-currentFinancialInstruments 2024-10-31 14392434 core:CostValuation core:Non-currentFinancialInstruments 2023-10-31 14392434 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-10-31 14392434 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-10-31 14392434 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-10-31 14392434 core:Non-currentFinancialInstruments 2024-10-31 14392434 core:Non-currentFinancialInstruments 2023-10-31 14392434 core:ShareCapital 2024-10-31 14392434 core:ShareCapital 2023-10-31 14392434 core:RetainedEarningsAccumulatedLosses 2024-10-31 14392434 core:RetainedEarningsAccumulatedLosses 2023-10-31 14392434 dpl:Item1 2023-11-01 14392434 dpl:Item1 2024-10-31 14392434 dpl:Item1 2022-10-13 14392434 dpl:Item1 2023-10-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 14392434
England and Wales

 

 

 


Abridged Accounts


for the year ended 31 October 2024

for

YOUNGMAN THERAPY LIMITED

 
 
Notes
 
2024
£
  2023
£
Fixed assets      
Tangible fixed assets 3 335    133 
335    133 
Current assets      
Debtors 33,009    16,089 
Cash at bank and in hand 15    113 
33,024    16,202 
Creditors: amount falling due within one year (22,441)   (16,239)
Net current assets 10,583    (37)
 
Total assets less current liabilities 10,918    96 
Net assets 10,918    96 
 

Capital and reserves
     
Called up share capital 4 1    1 
Profit and loss account 10,917    95 
Shareholders' funds 10,918    96 
 


For the year ended 31 October 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006 the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the director on 28 July 2025 and were signed by:


-------------------------------
Jodie Lee-Anne Youngman
Director
1
General Information
YOUNGMAN THERAPY LIMITED is a private company, limited by shares, registered in England and Wales, registration number 14392434, registration address 45 Thomas Stock Gardens, Abbeymead, Gloucester, Gloucestershire, GL4 5GH.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by Section 1A of the standard)
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Taxation
Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted
Dividends
Proposed dividends are only included as liabilities in the statement of financial position when their payment has been approved by the shareholders prior to the statement of financial position date.
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Computer Equipment 33% Straight Line
2.

Average number of employees

Average number of employees during the year was 1 (2023 : 1).
3.

Tangible fixed assets

Cost or valuation Computer Equipment   Total
  £   £
At 01 November 2023 199    199 
Additions 403    403 
Disposals  
At 31 October 2024 602    602 
Depreciation
At 01 November 2023 66    66 
Charge for year 201    201 
On disposals  
At 31 October 2024 267    267 
Net book values
Closing balance as at 31 October 2024 335    335 
Opening balance as at 01 November 2023 133    133 


4.

Share Capital

Allotted, called up and fully paid
2024
£
  2023
£
1 Class A share of £1.00 each  
 

2